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Progressive myoclonus epilepsy (PME) is a syndrome characterized by myoclonic seizures (lightning-like jerks), generalized convulsive
seizures, and varying degrees of neurological decline, especially ataxia and dementia. Previously, we characterized three pedigrees of
individuals with PME and ataxia, where either clinical features or linkage mapping excluded known PME loci. This report identiﬁes
a mutation in PRICKLE1 (also known as RILP for REST/NRSF interacting LIM domain protein) in all three of these pedigrees. The
identiﬁed PRICKLE1 mutation blocks the PRICKLE1 and REST interaction in vitro and disrupts the normal function of PRICKLE1 in
an in vivo zebraﬁsh overexpression system. PRICKLE1 is expressed in brain regions implicated in epilepsy and ataxia in mice and
humans, and, to our knowledge, is the ﬁrst molecule in the noncanonical WNT signaling pathway to be directly implicated in human
epilepsy.Introduction
More than a dozen clinico-molecular forms of progressive
myoclonus epilepsy (PME) are known, including Unver-
richt-Lundborg disease (MIM 254800 resulting from
CSTB mutations [MIM 601145]), Lafora disease (MIM
254780 resulting from EPM2A [MIM 607566] or NHLRC1
[MIM 608072] mutations), the family of neuronal ceroid
lipofuscinoses (with a variety of molecular defects includ-
ing PPT1 [MIM 256730], CLN4 [MIM 204300], and CLN5
[MIM 256731] mutations), and myoclonic epilepsy with
ragged red ﬁbers (MERFF [MIM 545000] with mitochon-
drial t-RNA mutations). Previously, we characterized three
families with individuals affected with PME and ataxia but
normal brain imaging, where either clinical features or
linkage mapping excluded known PME loci.1–3
This report identiﬁes a mutation in PRICKLE1 (MIM
608500) in all three of these pedigrees. PRICKLE1 is part
of the noncanonical or planar cell polarity (WNT/PCP)572 The American Journal of Human Genetics 83, 572–581, Novempathway, in which some WNT family members activate a
b-CATENIN (CTNNB1 [MIM 116806])-independent path-
way.4 In Drosophila and vertebrates, the WNT/PCP path-
way likely regulates cell polarization.5 Depleting Prickle
genes in the zebraﬁsh embryo alters the convergent-exten-
sion movements essential for gastrulation and disrupts
normal calcium signaling.6–8 PRICKLE1 is part of a gene
family encoding proteins containing a highly conserved
PET domain, which mediates Prickle1-protein-binding
interactions.6,9–11 Prickle1 was discovered independently
based on its ability to bind and functionally interact with
the RE1-SILENCING TRANSCRIPTION FACTOR (REST
[MIM 600571], which was thus separately named Rilp,
for REST/NRSF interacting LIM domain protein), an essen-
tial regulator of neural genes.12,13 The PRICKLE1mutation
identiﬁed in this study is located in the PET domain and
disrupts the PRICKLE1 and REST interaction in vitro and
alters the normal function of PRICKLE1 in an in vivo
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Figure 1. Pedigrees of the Affected Families, Representative Sequences, and Evolutionary Comparison of the Altered PRICKLE1
Amino Acid
Nine nuclear families from three pedigrees including 23 subjects with progressive myoclonus epilepsy and ataxia (pink symbol). Boxes on
pedigrees indicate individuals previously reported by Berkovic et al.1 (A), El-Shanti et al.2 (B), and Straussberg et al.3 (C). Dotted lines
indicate individuals believed to be related, but the exact relationship was unknown. Subjects who probably had the familial syndrome
but were not personally examined are shown in orange. Shared chromosome 12 haplotypes of affected subjects are shown on the top right.
Haplotypes were remarkably stable within nuclear families and extended pedigrees. Individuals with epilepsy or ataxia, clinically distinct
from the familial syndrome (green and purple symbols), did not share the haplotypes or have the PRICKLE1 mutation. Representative DNA
sequence chromograms from normal, carrier, and affected (mutant) individuals are in the bottom left panel with the red asterisks denoting
the position of the abnormal nucleotide. Amino acid sequence alignment surrounding the altered amino acid for PRICKLE proteins in
multiple species. pk1, Prickle1 protein; pk2, Prickle2 protein; esn, espinas protein; zfish, zebrafish. Accession numbers for the protein
sequences are: human-pk1, NP_694571; human-pk2, NP_942559; mouse-pk1, NP_001028389; mouse-pk2, NP_001074615; platypus-
pk1, XP_001505284; platypus-pk2, XP_001508261; chicken-pk1, XP_416036; chicken-pk2, XP_001234704; frog-pk1, NP_001016939;
frog-pk-2, NP_001103517; zfish-pk1, NP_899185; zfish-pk2, NP_899186; fruit fly-pk1, NP_724534; fruit fly-esn, CAB64381; worm-pk1,
NP_741435. The amino acid altered in the families and the corresponding amino acid in Prickle proteins from other species are boxed in red.Material and Methods
Subjects
Clinical details of the three pedigrees were previously described;1–3
pedigree B was subsequently expanded with eight more affecteds
identiﬁed in three nuclear families. Clinical studies were approved
by the Institutional Review Boards of the Tel Aviv Sourasky Medi-
cal Center and the Jordan University of Science and Technology.
Informed consent was obtained from participating subjects and
their legal guardians. The control brain specimens were obtained
from a 60-year-old male with cirrhosis who died suddenly ofThe Americaatherosclerotic heart disease, after exemption by the Institutional
Review Board of the University of Iowa and within guidelines
established by Iowa statute.
Fine Mapping and Haplotyping
Microsatellite markers within the chromosome 12 pericentro-
meric linkage region were selected from the Marshﬁeld human
linkage map. Genotyping of 47 individuals from 3 families (Fig-
ure 1) was performed by the Australian Genome Research Facility.
Marker order is based on the current human sequence map (NCBI
Build 36.3).n Journal of Human Genetics 83, 572–581, November 7, 2008 573
Resequencing
PRICKLE1 amplicons (Table S2 available online) were sequenced
with an automated ABI sequencer with dye terminator chemistry.
After DNA ampliﬁcation, unincorporated PCR primers and dNTPs
in the sample were removed prior to sequencing by isolation of the
desired band in a 2% agarose gel, followed by column puriﬁcation.
Sequences were analyzed with the computer program PHRED,
which calls the bases, and PHRAP that assembled the sequence
on a PC.
Control Genotyping
The 1054 individuals from the HGD-CEPH panel and the 300
Middle Eastern individuals were genotyped with the Taqman (ABI)
assay on an ABI 7900 HT Fast Real Time PCRmachine with the fol-
lowing primers according to manufacturer’s instructions: PR1ex4-
ex4F, GAAAAAAGAGTTGCAGGTGTTCAGT; PR1ex4-ex4R, TTAAT
TGTTCCTCTTCCCAGTGCTT; PR1ex4-ex4V1, VIC, CTCAGCGGA
AGAAA; PR1ex4-ex4M1, FAM, CTCAGCAGAAGAAA.
The entire PRICKLE1 gene was also directly resequenced in an
additional 288 individuals, including 96 individuals of Jorda-
nian-Palestinian ancestry.
Immunohistochemistry and Immunostaining
Protocols
For mouse sections and HeLa cells, the solution used was PBS 13
Dulbecco’s (pH 7.4) and the blocking solution for rabbit antibodies
used was serum-free blocking media (Dako, X0909). For mouse
combinedwith rabbit antibodies, we usedM.O.M.Mouse Ig Block-
ing Reagent (Vector, BMK-2202); add 2 drops of stock solution to
2.5 ml of PBS. For human sections, the solution used was PBS 1X
Dulbecco’s (pH 7.4) and the blocking solution was serum-free
blocking media (Dako, X0909).
Antibodies
Rabbit polyclonal antibody to mouse Prickle1 was produced with
amino acids 808–822 by A.G.B. and with amino acids 339–514 by
D.A. Speciﬁcity for Prickle1 and not Prickle2 was conﬁrmed by im-
munostaining of myc-tagged cDNAs encoding Prickle1 or Prickle2
proteins into HeLa cells (data not shown). NeuN (Chemicon),
GFAP (Dako), myc 9E10 (Sigma), and GFAP (Santa Cruz) anti-
bodies were used at a 1:400–1:500 dilutions for immunohisto-
chemistry and immunoblotting. Mouse and rabbit antibodies
were diluted in M.O.M. Diluent (600 ml of protein concentrate
stock solution added to 7.5 ml of PBS [Vector, BMK-2202]). Se-
quential rabbit antibodies were diluted in PBS 1X. Secondary
antibodies were diluted 1/500 in blocking for mouseþrabbit
antibodies or in PBS for rabbit antibody.We used the goat anti-rab-
bit IgG (Fab0)2-Alexa Fluor 568 conjugated antibody (Invitrogen,
A21069) for the anti-GFAP antibody and the goat anti-mouse
IgG (Fab0)2-Alexa Fluor 568 conjugated Ab (Invitrogen, A11019)
for anti-NeuN antibody. We used the goat anti-rabbit IgG (Fab0)2-
Alexa Fluor 488 conjugated Ab (Invitrogen, A11070) for the
Prickle1 antibodies. The nuclear counterstain To-Pro3 (Invitrogen,
T3605) was diluted 1/2000 in PBS 1X or DAPI. Slides were
mounted with Vector Labs, H-1000.
Staining Protocol, Mouse Sections
Procedure. Procedures were performed at room temperature or as
indicated. Sections were deparafﬁnized with autostainer program
#3 and rehydrated with ddH2O. To perform antigen retrieval by
microwave, citrate buffer (pH 6.0)was prewarmed for ~30 s in a Tef-
lon Coplin jar, and slides were added under the following condi-
tions: restriction temperature, þ95C; wattage, #6 (601 W); pulse574 The American Journal of Human Genetics 83, 572–581, Novemb5min, hold 5min (nomicrowave applied), pulse 5min, then slides
were left in the dish to cool to room temperature for about 20min.
Next, slideswerewashed inPBS1X (pH7.4), 3x3min. Sectionswere
permeabilizedwith 0.1%TritonX-100 inPBS for 10min,washed in
PBS 1X (pH 7.4), 3x3 min. Blocking was performed for rabbit and
mouse primary antibodies together by applying the working solu-
tion of M.O.M. mouse Ig blocking reagent X1 hr, then PBS 3x3
min, then working solution M.O.M. diluent for 5 min.
Primary Antibodies. Serum-free blocking media was added for
1 hr, then primary antibodies were added at the following dilu-
tions: rabbit anti-prickle 1 antibodies 1/250-1/375 were added
with mouse anti-NeuN (Chemicon, MA13377) 1/500 or rabbit
anti-prickle 1 afﬁnity-puriﬁed antibody 1/250-1/375 was added
followed by rabbit anti-GFAP Ab (Dako, Z0344) 1/1000 and stored
in a slide folder at þ4C.
Sequential Stainings. The following variation was used. Sections
were blocked (serum-free protein block) for 30 min, then primary
antibody (anti-GFAP antibody) was added for 1 hr, then washed
with PBS 1X (pH 7.4), 6 times for 3 min, and then the secondary
antibody-conjugated ﬂuorophore was added (in the dark) for
30 min. The slide was then washed with PBS 1X (pH 7.4), 6x for
3 min. Nuclear counterstain (in the dark) was then added for
5 min. Slides were then rinsed in PBS 1X and mounted in Vecta-
Shield and stored in slide-folder at þ4C. Nuclei were viewed in
the Far red channel (647 nm Ex). Anti-Prickle1 antibodies were
viewed in the green channel (488 nm Ex), and anti-GFAP or
anti-NeuN antibodies were viewed in red channel (568 nm Ex).
Staining Protocol, Human Sections
Procedure. Procedures were performed at room temperature or as
indicated. Sections were deparafﬁnized (with an autostainer)
and rehydrated with ddH2O. Antigen retrieval was performed
by microwave staining. Citrate buffer (pH 6.0) was prewarmed
in the microwave for ~30 s in a Teﬂon Coplin jar. Slides were
then added with temperature restriction: þ95C, wattage: #6
(601 W), pulse 5 min, hold 5 min (no microwave applied), pulse
5 min. Slides were then cooled to room temperature for about
20 min, washed in PBS 1X (pH 7.4), 3x for 3 min, and permeabi-
lized with 0.1% Triton X-100 in PBS for 10 min, washed in PBS
1X (pH 7.4), 3x3 min blocked with serum-free blocking media
for 1 hr. Primary antibodies were added for 1 hr, then washed
with PBS, 6x for 3 min, secondary antibodies were added in the
dark for 1 hr, then washed with PBS, 6x for 3 min. Slides were
mounted with VectaShield and sections were stored in a slide
folder at þ4C.
Primary Antibodies. Primary antibodies were diluted in PBS 1X.
Rabbit anti-prickle 1 antibody 1/250-1/375 and mouse anti-
NeuN (Chemicon,MA13377) 1/500were used together, and rabbit
anti-prickle 1 antibody 1/250-1/375 and rabbit anti-GFAP Ab
(Dako, Z0344) 1/1000 were used sequentially. Goat anti-rabbit
IgG (Fab0)2-Alexa Fluor 488 conjugated antibody (Invitrogen,
A11070) secondary antibody was diluted 1/500 in PBS. To-Pro3
(Invitrogen, T3605) was diluted 1/2000 in PBS 1X and was used
as the nuclear counterstain. Slides were mounted with VectaShield
(Vector Labs, H-1000).
Sequential Stainings. After the ﬁrst primary and secondary anti-
bodies were applied, slides were blocked (serum-free protein
block) for 30 min, and then the second primary antibody was ap-
plied for 1 hr, then the slides were washed in PBS 1X (pH 7.4), 6x
for 3 min, and then the second secondary antibody-ﬂuorophore
conjugated was added in the dark for 30 min, and then washed
in PBS 1X (pH 7.4), 6x for 3 min. Nuclear counterstain was then
added (in the dark) for 5 min, and slides were rinsed with PBSer 7, 2008
1X, and mounted in VectaShieldand and stored in a slide-folder at
þ4C. Nuclei are viewed in the far red channel (647 nm Ex), anti-
Prickle1 antibodies are viewed in the green channel (488 nm Ex),
and anti-NeuN or GFAP antibodies are viewed in red channel (568
nm Ex).
HeLa Cell Staining
Mouse monoclonal anti-Myc 9E10 (Sigma) 1/1000 was added
(EGFP viewed directly in green channel), then PBS was added 6
times for 3 min followed by secondary antibodies in the dark for
1 hr, then PBS 6 times for 3 min, and slides were then mounted
with VectaShield and double labeled sections were stored with
Ms þ Rb Abs in slide folder at þ4C.
Confocal Microscopy
All confocal microscopy was performed on a Zeiss 510 Confocal
Microscope at the University of Iowa or on a Leica confocal micro-
scope at Stanford University. The thickness of the confocal images
and all details of exposure time are embedded within the digital
photographs used in this manuscript and available upon request.
Plasmids
The full-length human PRICKLE1 cDNA in the PCR-bluntII-TOPO
(Open Biosystems) was cloned into the EcoRI (50) and XhoI (30)
sites of the pCS2þ vector, with the EGFP epitope added in-frame
to the 30 end of the gene by PCR site-directed mutagensis/chimer-
agnesis. The R104Q encoding mutation was introduced by site-
directed mutagenesis, and the entire cDNA was resequenced after
introduction of the mutation to insure that no additional muta-
tions were introduced. Myc-RESTwas the same construct used pre-
viously to deﬁne the Prickle-REST interaction.12,13
Transfections
Transfections into HeLa cells were performed as previously de-
scribed.12,13
Nuclear REST Measurement. To measure the impact of the
PRICKLE1 mutation on the localization of REST, cells transfected
with wild-type and myc-REST or mutant PRICKLE1 and myc-
REST and quantiﬁed with a variation of the method previously re-
ported.14,15 All GFPþ/mycþ cells were counted and a score of 4
was assigned for myc nuclear ﬂuorescence much greater than
myc cytoplasmic ﬂuorescence, 3 for myc nuclear ﬂuorescence
greater thanmyc cytoplasmic ﬂuorescence, 2 for myc nuclear ﬂuo-
rescence equal to myc cytoplasmic ﬂuorescence, 1 for myc nuclear
ﬂuorescence less than myc cytoplasmic ﬂuorescence, and 0 for
myc nuclear ﬂuorescencemuch less thanmyc cytoplasmic ﬂuores-
cence. The mean REST nuclear score was calculated for 100 GFPþ/
mycþ cells in each condition.
Coimmunoprecipitations
Coimmunoprecipitations with slight variations as previously de-
scribed.12,13 In brief, myc-mouse REST and GFP-human Prickle1
plasmids were cotransfected into HeLa cells according to the Lip-
ofectamine 2000 protocol. After 48 hr incubation, cells were lysed
with 300 ml cold NET-N þ Roche Protease Inhibitor. Lysates were
sonicated 3 times for 4 s. 60 ml of the crude lysates were removed
and mixed with 110 ml of denaturing loading buffer. The remain-
ing lysates were precleared by adding 5 ml of anti-rabbit beads and
rotating at room temperature for 20 min. The beads were removed
by centrifuging samples brieﬂy at 10,000 rpm and removing the
supernatant. Precleared lysates were then mixed with 10 ml rabbit
anti-GFP conjugated beads (Santa Cruz) and rotated for 2 hr atThe America4C, followed by 30 min rotation at room temperature. The super-
natant was removed and the beads rinsed 3 times with 500 mL of
cold NET-N lysis buffer. After rinsing, 80 ml of denaturing loading
buffer was added to the immunoprecipitated samples. 15 ml of
IP lysates or 10 ml of crude lysates were loaded onto a 10% SDS-
PAGE gel, ran for 75 min at 200V, and electroblotted overnight
at 140 mA. Membrane was incubated 1:2000 anti-GFP (Roche)
or anti-myc (Sigma) for 4 hr at 4C.
PCR Conditions for Sequencing
Primers used are listed in Table S2. For exons 2–8, the mix used for
PCR was: 2 ml DNA at 20 ng/ml, 2 ml 103 NH4 reaction buffer, 2 ml
dNTP (5mM), 0.75 ml MgCl2 (50mM), 0.2 ml Biolase Taq (5 mm/ml),
0.5 ml forward primer, 0.5 ml reverse primer (20 mMper primer), add
DDH2O to 20 ml. For exon 1, Invitrogen Platinum Pfx DNA poly-
merase was used. PCR cycling began after 10 min at 94C as fol-
lows: (94C, 45 s; annealing temperature, 30 s, 72C, 45 s)335 cy-
cles, followed by 72C for 8 min, then 4C until removed from
thermocycler.
Zebraﬁsh Constructs and Analysis
Zebraﬁsh prickle cDNAs and wild-type and mutant (R/ Q) PCR
products were cloned into the Gateway vector system (Invitro-
gen). Both myc-tagged and untagged forms were created. Syn-
thetic RNA was made with the mMessage machine kit (Ambion)
and injected at the 1–8 cell stage. Alterations to gastrulationmove-
ments were monitored by live image capture at 20 hr postfertiliza-
tion and older. Additionally, embryos were ﬁxed at the 8–10
somite stage for whole-mount in situ hybridization with the
molecular marker MyoD, which labels the midline as well as the
developing somites. Equivalent protein expression was veriﬁed by
myc-immunostaining and western blotting.
Statistical Analysis
The results of the zebraﬁsh injectionswere subjected to the Fisher’s
exact test with the following contingency numbers: wild-type Zfsh
pk1: 6 normal embryos, 36 defective embryos; mutant Zﬁsh pk1:
20 normal embryos, 30 defective embryos; total: 26 normal em-
bryos, 66 defective embryos.
Results
We analyzed disease features and genetics in three consan-
guineous Middle-Eastern pedigrees with autosomal-reces-
sive progressive myoclonic epilepsy syndromes with
ataxia1–3 that most closely resembled Unverricht-Lund-
borg disease, but without mutations in CSTB. Pedigree A
(Figure 1) from Northern Israel was originally reported as
progressive myoclonus epilepsy (a new form of Unver-
richt-Lundborg disease; EPM1B) beginning between 5
and 10 years; individuals were seen in adolescence or adult
life and difﬁculty walking prior to onset of myoclonus was
reported but not directly observed.1 Part of pedigree B was
seen in Jordan when subjects were young and the impres-
sive feature was an early-onset ataxia with later myoclonus
and seizures.2 Re-evaluation subsequently showed features
of progressive myoclonus epilepsy that was also present in
newly identiﬁed members of this pedigree residing in Jor-
dan and Northern Israel. Similarly, pedigree C was initiallyn Journal of Human Genetics 83, 572–581, November 7, 2008 575
regarded as a predominant ataxic syndrome when children
were examined in the ﬁrst decade, but later re-examination
showed ﬂorid progressive myoclonic epilepsy.3 The three
affected children had impaired upgaze that was also ob-
served in some affected members of pedigrees A and B. Fea-
tures of a mild sensory neuropathy seen in pedigree C were
not seen in the other families.
In all three pedigrees, comprising nine nuclear families,
ataxia began at 4 to 5 years and evolved into an unequivo-
cal PME phenotype with ataxia. In many forms of PME,
cognitive decline is severe and generally occurs early; how-
ever, in this disorder intellect is usually preserved. Further-
more, in all affected individuals tested, brain magnetic
resonance imaging gave unremarkable results. Table 1
summarizes the clinical and molecular features compared
to Unverricht-Lundborg disease.
Previous linkage analysis mapped the disease locus in
pedigree A and part of pedigree B (Figure 1) to the pericen-
tromeric region of chromosome 12.1,2 Pedigree B was next
expanded considerably, and in all three pedigrees, haplo-
type analysis of microsatellite markers showed an identical
haplotype over 12 Mb in pedigrees A and B, whereas pedi-
gree C shared only the distal 250,000 base pairs with ped-
igrees A and B (Figure 1). Pedigrees A and B shared the same
family name and were thought to be distantly related but
the relationship could not be established with genealogical
information for 5–6 generations. Pedigree C resided in a dif-
ferent village, had a different family name, and elders de-
nied a connection to the family name of pedigrees A and
B and to their villages.
Resequencing the entire coding region and intron-exon
boundries of 47 genes in the original linkage region (Tables
S1 and S2) revealed a single, shared, missense-nucleotide
change in the coding region of PRICKLE1 in all three fam-
ilies (c.311G/ A [R104Q]; Figure 1, bottom left). The al-
tered amino acid in PRICKLE1 lies within the highly con-
served PET domain and is invariant in evolution from
humans to worms and in the related PRICKLE2 and
Drosophila Espinas proteins (Figure 1, bottom right). This
nucleotide change segregated with the clinical phenotype
in all three pedigrees and was neither present in any of
1054 individuals from the CEPH-HGD control DNA sam-
ples,16 nor found in 300 samples from unrelated Middle-
Eastern individuals without epilepsy. Resequencing the en-
tire PRICKLE1 coding region showed no other variants in
another 288 control individuals without PME (including
96 Middle-Eastern individuals).
Taken together, the high degree of conservation of the
residue affected by the missense change, the absence of
the identiﬁed nucleotide change in more than 1300 con-
trols (2600 chromosomes), and the lack of other PRICKLE1
variants in nearly 300 additional controls strongly support
that the PRICKLE1 gene mutation causes this autosomal-
recessive, progressivemyoclonus epilepsy-ataxia syndrome.
Prickle1 is expressed in multiple brain regions through-
out mouse embryonic development, including regions
implicated in epilepsy such as the hippocampus, cerebral576 The American Journal of Human Genetics 83, 572–581, Novemcortex, and thalamus, as well as the primitive cerebel-
lum17–20 (and data not shown). We performed immuno-
histochemical analysis with two different Prickle1-speciﬁc
antibodies, each directed against a distinct epitope. In this
way we also detected Prickle1 expression in the postnatal
murine thalamus, hippocampus, cerebral cortex, and cere-
bellum (Figure 2). Costaining these tissues with the neu-
ron-speciﬁc marker NeuN and the glia-speciﬁc marker
GFAP demonstrated that Prickle1 is speciﬁcally expressed
in neurons, but not in glia (Figures 2C, 2D, 2G, 2H, 2K,
and 2L; cerebellum costaining not shown). Similarly, in
human adult thalamus, hippocampus, cerebral cortex,
and cerebellum, PRICKLE1 is in neurons rather than glia
(Figure 3; GFAP staining not shown). These ﬁndings dem-
onstrate that PRICKLE1 is expressed in multiple areas of
the brain thought to be involved in generating seizures
(neurons of thalamus, hippocampus, and cerebral cortex)
and ataxia (cerebellar neurons).
To evaluate the functional effect of this mutation on
PRICKLE1-partner protein interactions, we tested whether
mutant PRICKLE1 can coimmunoprecipitate REST (Fig-
ure 4). Although, as previously described, wild-type
PRICKLE1 binds REST directly,12,13 mutant PRICKLE1 fails
to bind REST in vitro. Furthermore, because REST nuclear
localization is altered in brains from patients with Hun-
tington’s disease with known mutations in Huntingtin,21
we tested whether mutant PRICKLE1 affected the subcellu-
lar localization of REST. Indeed, in HeLa cells, immunoloc-
alization shows that whereas overexpression of wild-type
PRICKLE1 results in cytoplasmic retention of REST, overex-
pressed mutant PRICKLE1 fails to retain REST in the cyto-
plasm (representative cells are shown in Figure 5A). To
quantify the effect of mutant PRICKLE1 on REST nuclear
localization, we counted cells based on REST expression
in the cytoplasm, nucleus, or both cytoplasm and nucleus,
in cells cotransfected with RESTþPRICKLE1 versus REST þ
mutant PRICKLE1 and found signiﬁcantly increased nu-
clear REST in cells cotransfected with mutant PRICKLE1
(Figure 5B). Therefore, the identiﬁed PRICKLE1 mutation
Table 1. Comparison of the Progressive Myoclonus
Epilepsy-Ataxia Syndrome Described Here to Classical
Unverricht-Lundborg Disease
Progresssive Myoclonus
Epilepsy-Ataxia
Syndrome
Unverricht-Lundborg
Diseasea
First symptom ataxia around age 4 yr myoclonic or
tonic-clonic seizures
Seizure onset: mean 7 yr 10–11 yr
Seizure onset: range 5–10 yr 6–16 yr
Progressive features worsening myoclonus,
ataxia, impaired up-gaze
worsening myoclonus,
ataxia
Cognitive decline mild or absent mild or absent
Mode of inheritance autosomal recessive autosomal recessive
Linkage 12p11–q13 21q22.3
Gene PRICKLE1 Cystatin B
a Modified and updated from Berkovic et al.1ber 7, 2008
Figure 2. Expression of Prickle1 in Postnatal Mouse Brain
Prickle1 expression in cortex (A–D), hippocampus (E–H), cerebellum (I, J), and thalamus (K, L). For (A), (B), (E), (F), (I), and (J),
Prickle1 antibody, raised against epitope corresponding to amino acids 339–514 of Prickle1, is labeled with green secondary, nuclear
staining is in red. For (C), (D), (G), (H), (K), and (L), Prickle1 antibody, raised against epitope corresponding to amino acids 808–
822 of Prickle1, is labeled in green. In (C), (D), (G), (H), (K), and (L), nuclear staining is in blue. In (C), (G), and (K), GFAP staining
is in red. In (D), (H), and (L), NeuN, staining is in red. Arrows point to representative cerebellar Purkinje cells. 3v, third ventricle
from coronal section; CA1, CA2, CA3, hippocampal Cornu Ammonis subregions; cb, cerebellum; cx, cerebral cortex; DG, dentate gyrus;
hpc, hippocampus; th, thalamus. Magnification is 103 in (A), (E), and (I); 203 in (B), (F), (J), (K), and (L); 603 in (C), (D), (G),
and (H). (A), (B), (E), (F), (I), and (J) are from P7 brain, (C), (D), (G), (H), (K), and (L) are from adult brain. (A)–(J) are from sagittal
sections, (K) and (L) are coronal sections. A representative sample of sagittal sections from a P19 brain at multiple magnifications can be
found in Figure S1.disrupts both normal REST-binding and REST subcellular
localization.
To investigate whether the mutant Prickle1 protein is
functionally different from the wild-type in vivo, we
injected zebraﬁsh embryos with RNA encoding either
wild-type or mutant zebraﬁsh prickle1. As previously dem-
onstrated, overexpressing wild-type prickle1 alters gastrula-
tion, resulting in a reduced anterior-posterior length (Fig-
ures 6A and 6B) and lateral expansion of somites (Figures
6C and 6D). Here, we further demonstrated that, compared
to wild-type Prickle1, expressing similar levels of R104Q
mutant Prickle1 showed a signiﬁcantly less pronounced
phenotype (Figure 6E). Thus in a zebraﬁsh overexpression
assay, the identiﬁed PRICKLE1 mutation alters the in vivo
function of Prickle1.The AmericaDiscussion
The ﬁnding of a shared haplotype and identical PRICKLE1
mutation in three separately ascertained families of the
same ethnic group with PME suggests a founder effect.
The variation reported in the original three reports is ex-
plained by the differences in ages of the subjects ascer-
tained in the earlier studies. Longitudinal assessment
showed a uniform phenotype summarized in Table 1.
The genealogical data and smaller ancestral haplotype
found in family C suggests that this family separated earlier
from the common ancestral line.
The identiﬁcation of a PRICKLE1 mutation causing this
PME-ataxia syndrome raises several issues regarding the
biology of PRICKLE1 and the pathophysiology ofn Journal of Human Genetics 83, 572–581, November 7, 2008 577
Figure 3. Expression of PRICKLE1 in Adult Human Brain
Low-power (A–D) and high-power (E–H) confocal images from immunostaining of adult human thalamus (A, E), hippocampus (B, F),
cerebral cortex (C, G), and cerebellum (D, H). PRICKLE1 staining is in green, NeuN is in red, and nuclear staining is in blue. Scale markers
are represented on the bottom right corner of each image.neurological disease in these affected individuals.
PRICKLE1 is part of the noncanonical or planar cell polar-
ity (WNT/PCP) signaling pathway. In vivo studies in de-
veloping ﬂies, frogs, and ﬁsh clearly demonstrated that
Prickle1 is important for planar polarity signaling. Re-
cently, mice lacking Prickle1 were shown to die early in
gestation, conﬁrming an essential role for Prickle1 in
development (H. Tao et al., 2008, Jap. Soc. Dev. Biol., ab-
stract). At least some PRICKLE1 functions seem to be pres-
ent in protein with the R104Q mutation because the mu-
tation does not affect PRICKLE1 protein expression nor
subcellular localization (Figure 5) and it still retains some
wild-type function in our zebraﬁsh overexpression system
(Figure 6).
Our in vitro studies suggest that PRICKLE1 normally
binds and translocates REST to the cytoplasm, thereby
preventing REST from silencing target genes. The
R104Q PRICKLE1 mutation lies within a known protein
binding domain and thus disrupts REST binding (Fig-
ure 4), blocking the normal transport of REST out of
the nucleus (Figure 5). These results suggest that tissues
expressing mutant PRICKLE1 contain constitutively ac-
tive REST which inappropriately downregulates REST tar-
get genes. This is signiﬁcant because in addition to silenc-
ing neuronal genes in nonneuronal cells and neuronal
precursors, REST also regulates target genes in mature
neurons.22 REST targets include ion channels and neuro-
transmitters, and the PME-ataxia syndrome may occur
when brain regions expressing mutant PRICKLE1 misex-
press these target genes. Although Prickle function was
implicated in the control of cell division and morphogen-
esis during zebraﬁsh neurulation23 and REST activity was578 The American Journal of Human Genetics 83, 572–581, Novembrecently described in ﬁsh and frogs,24 a role for the
PRICKLE/REST interaction during neurogenesis has not
yet been studied.
Figure 4. R104Q Mutant PRICKLE1 Has Impaired NRSF/REST
Binding
Coimmunoprecipitation of REST with wild-type (WT) or R104Q
mutant (MUT) encoding PRICKLE1 demonstrates decreased REST
binding for MUT PRICKLE1. MYC-REST and either GFP-tagged WT
or R104Q MUT PRICKLE1 plasmids were transfected into HeLa cells.
Cell lysates were prepared in RIPA buffer and immunoprecipitated
with agarose-conjugated anti-GFP antibody (A) or anti-MYC anti-
body (B). Immunoprecipitates (IP) were subjected to SDS-PAGE
followed by western blotting (WB) with MYC or GFP antibodies.
WB antibody noted to left of gels. The input (1/5) of immunopre-
cipitation is shown in the ‘‘Lys’’ lanes. Arrows to the right of the
gels note the position of MYC-REST and GFP-PRICKLE1.er 7, 2008
Figure 5. Subcellular Localization of Recombinant MYC-REST and WT or MUT PRICKLE1
(A) HeLa cells were transfected with MYC-REST and WT PRICKLE1 or MUT PRICKLE1, as noted on the top of the images in (A). Antibody
staining with ANTI-MYC antibody (red), ANTI-PRICKLE1 antibody (green), DAPI nuclear staining (blue), and MERGED confocal images are
noted on the left. Scale bar represents 9 microns. All confocal images were captured with identical exposure settings. The white arrow in
the merged WT-PRICKLE1þMYC-REST marks a cell with relatively less WT PRICKLE1 expressed versus the two other WT PRICKLE1-expressing
cells in the same panel. Note that increased REST in the nucleus is inversely proportional to WT PRICKLE1 expression, whereas the nuclear
REST signal is strong even in the presence of a strong MUT PRICKLE1 signal (bottom right).
(B) Quantification of nuclear REST in PRICKLE1 versus mutant PRICKLE1 cotransfections. Results are the mean (5SD) of 100 cells for each
group.PRICKLE1 has also been implicated in the canonical
WNT/b-catenin pathway.25 Mutations in EPM2A, which
cause Lafora disease—a severe form of PME with neurode-
generation—can affect the stability of the b-catenin com-
plex in the canonical WNT/b-catenin pathway by dephos-The Americaphorylating GSK3-b.26 Although the involvement of
PRICKLE1 and the inﬂuence of Epm2A on b-CATENIN
may be unrelated, it is possible that a common pathway
connects the effects of PRICKLE1 mutations to Lafora dis-
ease and WNT signaling. It is notable that many affectedFigure 6. Mutant prickle1 Shows De-
creased Activity In Vivo in Zebrafish
(A–D) Equivalent amounts of RNA encoding
wild-type zebrafish prickle1 (pk-wt) or
zebrafish prickle1 encoding the human
R104Q homologous amino acid (pk-mut)
were injected into zebrafish embryos and
assayed for convergence extension defects
by morphology (A) wild-type compared to
(B) pk-overexpression, anterior to the left
and with molecular markers to axial tissues
in (C) wild-type and (D) pk-overexpressing
embryos, anterior to the top.
(E) Decreased gastrulation defects are ob-
served in mutant prickle1 expressing em-
bryos compared to wild-type prickle ex-
pressing embryos. The mutant Prickle1
showed significantly decreased overexpres-
sion phenotype, with a p value of 0.01 by
the Fisher’s exact test.n Journal of Human Genetics 83, 572–581, November 7, 2008 579
individuals with PME respond to medications such as val-
proic acid, which also affects the WNT/b-catenin signaling
pathway through inhibition of GSK3-b.27,28 On the other
hand, valproic acid was also shown to alter inositol levels,
which would interfere with calcium regulation.29–31
It is not yet clear how a mutation in human PRICKLE1
leads to the PME syndrome, which is pathophysiologically
characterized by increased cortical hyperexcitability with
involvement of the cerebellum and probably other deep
gray matter nuclei as well.
Future analysis of the effects of speciﬁc point mutations
of Prickle1 in animal models will further elucidate the mo-
lecular mechanisms underlying this PME-ataxia syndrome.
Understanding the molecular and cellular basis of the dis-
ease may lead to improved diagnostic and therapeutic
approaches for afﬂicted individuals.
Supplemental Data
Supplemental Data include one ﬁgure and two tables and can be
found with this article online at http://www.ajhg.org/.
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